Panlabs Biologics

Panlabs Biologics is a Taiwan-based CRO and CDMO specializing in microbial strain improvement, fermentation, and bioprocess development. With a history dating back to 1971 and a proprietary library of over 20,000 microbial strains, the company provides end-to-end services from early-stage research to commercial-scale production. Its internal R&D pipeline focuses on high-value generic drugs, anticancer therapeutics including antibody-drug conjugate (ADC) payloads like Ansamitocin P-3 and Calicheamicin, and innovative biologic ingredients such as Lactobacillus-derived extracellular vesicles (Lactosome™). Panlabs serves a global clientele in the pharmaceutical, biotech, and nutraceutical industries, leveraging its expertise in microbial and enzyme engineering to deliver scalable manufacturing solutions.